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ABSTRACT
Dyskinesia hyperpyrexia syndrome is a rare medical emergency in Parkinson’s disease. It is characterized by continuous dyski-
nesia associated with hyperthermia, rhabdomyolysis, and alteration of the mental state. We present the case of a 74-year-old 
woman who presented with recurrent dyskinesia hyperpyrexia syndrome. Although some provocation factors and clinical man-
ifestations seem to be shared with parkinsonism hyperpyrexia syndrome, a clear distinction in management should be considered.
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Dyskinesia hyperpyrexia syndrome is a rare movement dis-
order emergency in Parkinson’s disease (PD). It is character-
ized by severe continuous dyskinesia associated with rhabdo-
myolysis, hyperthermia, and subsequent alteration of the mental 
state.1 We report a PD patient who presented with recurrent 
dyskinesia and hyperpyrexia syndrome. 
 
CASE REPORT
A 74-year-old woman who first presented with a resting trem-
or in her left hand at age 51 and had been treated with levodo-
pa since age 53 visited an emergency center for continuous gen-
eralized choreiform dyskinesia and high fever during the last 
24 hours. Six days before the onset of continuous dyskinesia, she 
had fractures of ribs after falling. The season was spring. She 
had been taking acetaminophen since the rib fracture, and no 
other medication was prescribed. She was alert, but visual hal-
lucination and disorientation were noted. Dyskinesia was too 
severe for her to lie on a bed safely, and body temperature was 
40.3°C. She had not eaten well for a few days because of appetite 
loss. Blood tests showed mild leukocytosis [white blood cell 
(WBC) 12,100/mm3], elevated creatine kinase (CK; 1,023 IU/mg), 
and urine myoglobin (58,611 μg/L). Blood urea nitrogen (BUN) 
was 35 mg/dL, and creatinine rose to 1.6 mg/dL. Sputum bac-
terial culture was sterile, but chest computerized tomography 
(CT) showed consolidation in both lower lobes, indicating as-
piration pneumonia. Intravenous ampicillin and sulbactam were 
prescribed empirically. She had been taking amantadine (200 
mg/day), an extended release (ER) form of pramipexole (1.075 
mg/day), and levodopa (375 mg/day) with benserazide for three 
years. On admission, amantadine and pramipexol were dis-
continued, and she was sedated with intravenous midazolam 
infusion in an intensive care unit. When she awakened after four 
days of sedation, the continuous dyskinesia disappeared. Fever 
subsided on the 1st day, and the serum CK level was normalized 
on the 6th day of admission.
During the 19 months after the first attack of serious dyskine-
sia, she remained stable taking amantadine (300 mg/day), prami-
pexole ER (1.075 mg/day), and levodopa (500 mg/day) with 
benserazide. She felt mild peak dose dyskinesia for 30 mins af-
ter taking each dose. Seven days before the second attack, she 
had fallen and experienced trauma to her left flank. She started 
to show fever and sweating two days before visiting the emer-
gency center for the second attack of continuous dyskinesia af-
ter an evening dose. The season was spring. She had been tak-
ing acetaminophen for three days, prescribed for flank pain. 
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No other nephrotoxic medication was prescribed. 
Her mental status was alert without confusion at the 
time of arrival, but after several hours, her dyskine-
sia grew worse and she became confused. Body tem-
perature was 39.2°C. Her blood test showed mild 
leukocytosis (WBC 10,090/mm3). Renal function 
was decreased with elevated BUN (50.3 mg/dL) and 
serum creatinine (1.17 mg/dL). Serum CK (661 IU/
L) and urine myoglobin (27,259 μg/L) levels were 
elevated (Figure 1). Although there were limitations 
due to motion artifacts, a chest CT scan showed ill-
defined ground-glass opacity in both lower lobes. 
No space-occupying inflammatory lesion was ob-
served. Since low C-reactive protein (1.7 mg/L), 
bacterial culture of sputum and a rapid influenza di-
agnostic test were negative, pneumonia was not con-
sidered as a fever source. Antibiotics were not pre-
scribed. We discontinued pramipexole and reduced 
the levodopa dose to 300 mg/day. After conservative 
treatment with intravenous hydration and antipyret-
ics, her continuous generalized dyskinesia disap-
peared 20 hours after the initial onset of dyskinesia. 
Mental status and body temperature returned to nor-
mal. Six days after the onset of dyskinesia, the serum 
CK level was normalized.
 
DISCUSSION
Dyskinesia hyperpyrexia syndrome is a rare com-
plication of PD. It is characterized by severe contin-
uous dyskinesia associated with rhabdomyolysis, 
hyperthermia, and subsequent alteration of the men-
tal state. Previously, only three cases had been re-
ported in the English literature since its first descrip-
tion in 2010 (Table 1). In all three previous cases, the 
patients were characterized by long-duration PD 
with motor symptom fluctuation on dopaminergic 
medication.1,3,4 In one case, ropinirole medication 
was added before the attack,4 while in the other cas-
es, no medication regimen change before the attack 
was reported.1,3 Two of the three patients suffered fe-
ver spiking before the attack.1,3 The underlying mech-
anisms of dyskinesia hyperpyrexia are still not well 
understood but are probably related to impairment 
of the dopamine buffering capacity of the striatum,4 
the administration of D-3 agonist,4 and thermostatic 
deregulation.3 Tapering off of dopaminergic agonist 
medication and continuous dopaminergic stimula-
tion seemed beneficial, but one case of dyskinesia hy-
perpyrexia syndrome despite continuous levodopa 
enteral infusion was also reported.4 In our patient, re-
current-onset continuous dyskinesias were reported. 
CK elevation was remarked in both events. Although 
Figure 1. Clinical course and laboratory results. Temporal changes in clinical and laboratory findings during the first (A) and second (B) at-
tacks of dyskinesia-hyperpyrexia syndrome. Arrows indicates first visit to emergency room. Marked areas designate the duration of continu-
ous dyskinesia. CK: creatine kinase, BT: body temperature.
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an underlying infection might have co-existed with 
hyperpyrexia, the relatively short duration of fever 
and immediate subsidence after the discontinuation 
of dyskinesia more strongly implies hyperpyrexia. 
In this circumstance, a diagnosis of dyskinesia hy-
perpyrexia syndrome was made.
This case showed a rare movement disorder emer-
gency, which occurred recurrently without recent 
dopaminergic medication changes. Prior traumas 
and fever spiking were followed by continuous dys-
kinesia, with subsequent serum CK and creatinine 
elevation. The symptoms probably resolved with le-
vodopa tapering and the discontinuation of dopa-
minergic medication. 
The patient shares some clinical characteristics of 
parkinsonism hyperpyrexia syndrome (PHS), such 
as hyperthermia and rhabdomyolysis. The provoca-
tion factors of PHS include infectious disease, trau-
ma, surgery, or treatment manipulation, especially 
the withdrawal of levodopa, which were observed 
in a previous cohort study.5 The underlying mecha-
nism is implicated by the sudden suppression of cen-
tral dopaminergic activity and alteration in the cen-
tral serotonin metabolism.
Considering the patient’s history of a recent fall, 
appetite loss and fever spiking preceding the attack 
of continuous dyskinesia in this case, some provoca-
tion factors seem to affect both PHS and dyskinesia 
hyperpyrexia syndrome. In contrast to PHS, dyski-
nesia hyperpyrexia syndrome is probably due to the 
excessive stimulation of central dopaminergic ac-
tivity. Since no dopaminergic medication had been 
changed in our patient, a reduced buffering capacity 
for dopaminergic medication could play a role. Trau-
mas, infection and dehydration could be related to 
alteration of the dopaminergic buffering capacity. 
Further investigation of the provocation factors of 
dyskinesia hyperpyrexia syndrome is warranted.
In PHS, treatment is based on intravenous hydra-
tion and an addition or increase in the dose of do-
paminergic medication. In contrast, dyskinesia hy-
perpyrexia syndrome should be treated with the 
reduction of dopaminergic medication. Consequent-
ly, rapid recognition and application of a treatment 
plan are essential in this life-threatening movement 
disorder emergency.
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Table 1. Overview of four affected individuals with dyskinesia hyperpyrexia syndrome
Authors
Age/
sex
Season
PD 
duration 
(years)
Suspected 
provocation  
factor
Symptoms
Duration of 
dyskinesia/
hyperpyrexia
Medication  
(mg/day)
Treatment
Gil-Navarro  
  and  
  Grandas1
68/F NA 12 NA
Generalized dyskinesia,  
  confusion, hallucination,  
  drowsiness, hyperpyrexia
Few days
Levodopa 750 
Pramipexole 4 
Amantadine 200
Pramipexol tapered  
  off quetiapine  
  25 mg added
Taguchi 
  et al.2
70/F Fall 13
Recent medication  
  change (pramipexole 
  IR→ER) 
Generalized dyskinesia,  
  hallucination,  
  hyperpyrexia
7 days
Levodopa 600 
Pramipexole 3
Reduction of  
  dopaminergic 
  drugs
Herreros- 
  Rodriguez  
  et al.3
83/F Summer 25 Seasonal variation
Generalized dyskinesia,  
  hyperpyrexia
Few days  
  (8 recurrent  
  episodes)
Levodopa 150 
Amantadine 100
Levodopa enteral  
  infusion 
Acebrón  
  Sánchez- 
  Herrera  
  et al.4
66/F Summer 16
Trauma/recent  
  medication addition 
  (ropinirole due to  
  RLS)
Generalized dyskinesia,  
  confusion, hallucination,  
  hyperpyrexia 
4 days
Levodopa 1,450 
  (enteral infusion) 
Amantadine 200  
Ropinirole 8
Reduction of  
  dopaminergic  
  drugs
IR: immediate release, ER: extended release, RLS: restless leg syndrome, PD: Parkinson’s disease.
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